E
Eric J. Topol
Researcher at Scripps Health
Publications - 1406
Citations - 162373
Eric J. Topol is an academic researcher from Scripps Health. The author has contributed to research in topics: Myocardial infarction & Angioplasty. The author has an hindex of 193, co-authored 1373 publications receiving 151025 citations. Previous affiliations of Eric J. Topol include Loyola University Chicago & Cleveland Clinic.
Papers
More filters
Journal ArticleDOI
Predictors of death and reinfarction at 30 days after primary angioplasty : The GUSTO IIb and RAPPORT trials
Sorin J. Brener,Stephen G. Ellis,Shelly Sapp,Amadeo Betriu,Christopher B. Granger,J. E. B. Burchenal,David J. Moliterno,Robert M. Califf,Eric J. Topol +8 more
TL;DR: Death and reinfarction after primary angioplasty are predominantly predicted by age, hemodynamic instability, and the attainment of TIMI 3 flow in the infarct artery.
Journal ArticleDOI
The role of maintenance of certification programs in governance and professionalism.
TL;DR: In recent years, physicians have been saddled with added regulatory burden after burden, compelled by numerous regulatory authorities, such as the Centers for Medicare & Medicaid Services, The Joint Commission, and state authorities.
Journal ArticleDOI
Trends in Prices of Popular Brand-Name Prescription Drugs in the United States.
TL;DR: Prices of brand-name drugs in the United States are likely to continue to increase, which warrants greater price transparency, and the need for price transparency is called for.
Journal ArticleDOI
Patients with acute coronary syndromes without persistent ST elevation undergoing percutaneous coronary intervention benefit most from early intervention with protection by a glycoprotein IIb/IIIa receptor blocker
Eelko Ronner,Eric Boersma,K.M. Akkerhuis,Robert A. Harrington,A.M. Lincoff,J.W. Deckers,Karl R. Karsch,Neal S. Kleiman,Alec Vahanian,Eric J. Topol,Robert M. Califf,Maarten L. Simoons +11 more
TL;DR: Patients treated with a platelet glycoprotein IIb/IIIa receptor blocker, and early percutaneous coronary intervention (within 24 h) had the lowest event rate in this post hoc analysis, suggesting 'watchful waiting' may not be the optimal strategy.
Journal ArticleDOI
Impact of Proton Pump Inhibitor Therapy on the Efficacy of Clopidogrel in the CAPRIE and CREDO Trials
Steven P. Dunn,Steven R. Steinhubl,Deborah Bauer,Richard Charnigo,Peter B. Berger,Eric J. Topol +5 more
TL;DR: In CAPRIE, clopidogrel was beneficial to non‐PPI users while apparently harmful to PPI users, and in CREDO, the efficacy ofClopidOGrel was not significantly affected by PPI use.